P1/2, N=1, Completed, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Completed

P2, N=12, Recruiting, National Heart, Lung, and Blood Institute (NHLBI)

P=N/A, N=80, Recruiting, AbbVie | Not yet recruiting --> Recruiting

In the current case, the BCR-ABL fusion was detected and CML was confirmed after the recurrence of splenomegaly. Subsequent treatment with a combination of flumatinib and ruxolitinib was demonstrated to be safe and effective.

P2/3, N=784, Completed, Eli Lilly and Company | Active, not recruiting --> Completed

P2, N=49, Completed, Incyte Corporation | Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: Aug 2025 --> Mar 2025

P=N/A, N=21, Completed, Sixth Affiliated Hospital, Sun Yat-sen University

In conclusion, we found that JAK3 mutations, especially JAK3 p.A573V and JAK3 p.M511I mutations, lead to poor prognosis of anti-PD-1 therapy through the STAT3/PD-L1 pathway. Tofacitinib is more suitable than anti-PD-1 antibody for JAK3 mutant PTCL patients.

P1/2, N=39, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

P=N/A, N=150, Completed, Bristol-Myers Squibb | Recruiting --> Completed | N=50 --> 150

BALB/c nude mice were utilized to construct a humanized immune system model to evaluate the efficacy of ruxolitinib in vivo...M2 macrophages promoted effector T cell exhaustion by downregulating 4-1BB. Thus, inhibition of the IL6/JAK pathway in M2 macrophages restored 4-1BB expression and T-cell cytotoxicity offering a promising therapeutic target for the treatment of HOXC6-overexpressing MSI-H CRC.

Consistent with clinical trials, entrectinib is tolerable and effective in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced/recurrent NSCLC.

P=N/A, N=708, Completed, AbbVie | Active, not recruiting --> Completed

P=N/A, N=600, Not yet recruiting, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University; Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

P1/2, N=12, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=47 --> 12 | Trial completion date: Dec 2024 --> Jun 2025

P2, N=160, Recruiting, Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University

P=N/A, N=204, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

P4, N=34, Not yet recruiting, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University

P4, N=47, Terminated, Incyte Corporation | N=100 --> 47 | Recruiting --> Terminated; The study was terminated due to lack of enrollment.

The JAK/signal transducer and activator of transcription (STAT) pathway is often activated in tumor cells of ALCLs, suggesting that it is a therapeutic target. The causal connection between baricitinib and lymphomagenesis remains unknown; however, this patient developed ALK-ALCL with TP53 mutations during baricitinib treatment.

P1, N=27, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

P1/2, N=50, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

P1, N=20, Not yet recruiting, University of Kansas Medical Center | Trial primary completion date: Dec 2025 --> Dec 2026

P1/2, N=96, Completed, University of Ulm | Trial completion date: Apr 2026 --> Apr 2024 | Active, not recruiting --> Completed

P2, N=330, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2029 --> Oct 2030 | Trial primary completion date: Jun 2025 --> Oct 2026

TRK inhibitors, particularly larotrectinib and entrectinib, were commonly used treatments. NTRK fusions are rare, with wide prevalence variability among cancer types. The findings highlight the need for standardized diagnostic methods and larger real-world studies to improve prevalence estimates and assess the impact of NTRK fusions on outcomes, ultimately aiding in the optimization of targeted treatments for affected patients.

In summary, no new safety issues were identified. On the basis of the pharmacokinetic results, no dose adjustment is required for patients with MF with mild or moderate hepatic impairment.

P3, N=438, Completed, AbbVie | Active, not recruiting --> Completed

P1/2, N=56, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Phase classification: P2 --> P1/2

P2, N=20, Recruiting, Innovaderm Research Inc. | Trial primary completion date: Feb 2025 --> Feb 2026 | Trial completion date: Feb 2025 --> Feb 2026

Here, we report the case of a patient with stage IIIA (cT2aN2M0) ROS1 fusion lung adenocarcinoma who achieved downstaging and completed resection after a 3-month treatment with entrectinib, resulting in a postoperative pathological stage of ypT1cN0M0. The patient continued adjuvant entrectinib therapy and has remained recurrence-free during follow-up, with 21 months since diagnosis and 18 months since surgery.

The main reason for the failure of chemotherapy therapies based on 5-Fluorouracil (5-Fu) is the development of resistance to 5-Fu in cancer patients, particularly those with colorectal cancer...Moreover, anti-TIMP-2 antibody or small molecule drug LY2784544 targeting the JAK-STAT signalling pathway can effectively reverse the resistance of CRC cells to 5-Fu. It is exactly TIMP-2 that mediates the resistance of CRC to 5-Fu through the JAK-STAT signalling pathway. Targeting drugs for TIMP-2 or the JAK-STAT signalling pathway are expected to be opportunities to reverse 5-Fu resistance in CRC.

Mechanistic studies revealed that while pacritinib inhibited the phosphorylation of JAK, STAT3, and IRAK1 in esophageal carcinoma cells, it is the suppression of the JAK/STAT3 pathway, rather than IRAK1, that is responsible for the synergistic effect with carboplatin. Our findings indicate that pacritinib possesses potent anti-tumor activity in esophageal carcinoma and enhances the efficacy of carboplatin through the suppression of JAK/STAT3 signaling, warranting further clinical investigation.

Time-varying use of systemic medications categorized as (1) methotrexate; (2) other older systemic medications; (3) anti-tumor necrosis factor (anti-TNF) biologics; (4) other biologics (targeting interleukin [IL]-12, IL-23, and IL-17); and (5) tofacitinib. In this cohort study, biologics targeting IL-12, IL-23, or IL-17 were associated with a lower rate of serious infection among older adults with psoriatic disease. These biologics may have important safety benefits for older adults with higher infection risk.

P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

P2/3, N=10, Eli Lilly and Company

P3, N=315, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Trial completion date: Dec 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 | Active, not recruiting --> Completed

Utilizing the JAK1 inhibitor Ruxolitinib effectively reversed BAIAP2L2-induced cellular processes such as proliferation, migration, invasion, and PD-L1 upregulation. Overall, our results emphasize that BAIAP2L2 plays a crucial role in driving tumor progression and immune evasion in HCC through the JAK1-mediated signaling pathway, thus proposing BAIAP2L2 as a promising therapeutic target for HCC treatment.

P3, N=425, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting --> Completed

P1, N=180, Recruiting, Incyte Corporation | N=108 --> 180

P4, N=180, Completed, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Recruiting --> Completed

P3, N=309, Active, not recruiting, Celgene | Trial completion date: Feb 2029 --> Aug 2032